menu

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

Program Information
Recommended
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
RestartResume
    FDA medical oncologists discuss the Sept 14, 2017, approval of MVASI, the first biosimilar approved in the US for the treatment of cancer.
    • Overview

      Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.

      Released on December 21, 2017

    Facebook Comments

    Programs 8/21/19

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.